MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ
Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.“It is a disappointment to discontinue the development program but our product candidates need to meet strict criteria to be approved for continued investments. Our other development programs progresses according to plan and our goal of positive cash flow and operating results 2013 remain unchanged,” said Peter Wolpert, CEO of Moberg